CYP1A1/2 Induction Reporter Assa

Confirm delete?

CYP1A1/2 Induction Reporter Assay Kit

Zoom

Cat No: 600670

Assay Kits - Cell-Based Assays

Early screening of a drug candidate’s potential to induce or inhibit CYP1A1/2 is a critical step in the drug development process. Cayman's CYP1A1/2 Induction Reporter Assay Kit is a novel method to assess CYP1A2 induction. Our Reverse Transfection Rep...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

kits assays measures measurements cytochromes P450s CYP450 CYPs heme-thiolates monoxygenases metabolizes endogenous compounds xenobiotics pollutants environmentals drugs enzymes metabolisms medications induction pharmacokinetics drug-drug interactions co-administered therapeutics CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4 CYP1A1 CYP1A2 detoxification metabolic polycyclic aromatic hydrocarbons cigarette smoke combustion arylamines heterocyclic amines char-broiled meats intermediates mutagenics carcinogenics inhibits toxicity low efficacy development primary humans hepatocytes livers cells tissues hepatocyte-like CBAs cell-based assays kits measures measurements cultured lines transfected genes promoter/enhancer sequences high-throughput assessments Surface transfection Expression protocols solid phases transient originus, Inc. incorporated University of Michigan U M US patents USPT 6897067 6902933 7056741 complexes DNA deoxyribonucleases proteins adherent endocytosis solution-phase plasmids secreted alkaline phosphatases SEAP inducer-activated transcription factors TFs signals signaling culture mediums luminescence-based 3-MC 3MC reverse reporter assay transfection

Product Overview:
Early screening of a drug candidate’s potential to induce or inhibit CYP1A1/2 is a critical step in the drug development process. Cayman's CYP1A1/2 Induction Reporter Assay Kit is a novel method to assess CYP1A2 induction. Our Reverse Transfection Reporter Assays have overcome many of the disadvantages of other transfection approaches. Cayman's CYP1A1/2 Induction Reporter Assay Kit consists of a 96-well plate coated with a transfection complex containing a Secreted Alkaline Phosphatase (SEAP) reporter construct regulated by the human CYP1A1/2 gene promoter. Cells grown on the CYP1A1/2 Reverse Transfection Strip Plate will introduce the reporter gene into the nucleus. Binding of inducer-activated endogenous transcription factors to the CYP1A1/2 promoter initiates a signal resulting in expression of SEAP which is secreted into the cell culture medium. Aliquots of medium are removed at time intervals beginning at about 24 hours and SEAP activity is measured simply by adding a luminescence-based alkaline phosphatase substrate provided in the kit. The kit is simple to use and can be easily adapted to high-throughput screening for potential CYP1A1 and CYP1A2 inducers.

Size	100 tests
Shipping	dry ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.